CUTIA-B (02487) rose more than 10%, with a gain of 10.11% to HK$7.19 by the time of writing, recording a turnover of HK$5.78 million.

Recently, CUTIA Group announced that the first batch of commercialized products of the imported original 4% minocycline hydrochloride foam (Anzuoqing®) has been shipped nationwide from its Wuxi facility. As the world's first and only topical 4% minocycline hydrochloride foam, it is indicated for the local treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients aged 9 and above.

Additionally, on October 17, CUTIA Group announced the nationwide shipment of the first batch of commercialized imported original finasteride spray (brand name: Fenjuve® Finjuve®) from Shanghai Pharmaceuticals International Supply Chain Co., Ltd. Sales officially commenced in China on October 20.

Caitong Securities noted that the company is an emerging player in the field of dermatological treatments, with its two core products demonstrating strong differentiation advantages. The gradual commercialization of these products is expected to drive performance growth.

Kaiyuan Securities highlighted that the company has established a diversified product portfolio covering hair disorders, skincare, and medical aesthetics, expressing optimism about its growth potential amid accelerated pipeline execution and commercialization.